Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erica L Mayer

Showing results (101-110 of 120) with videos related to

Pageof 12
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et alIngrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of the National Cancer Institute|December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort studyAna S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
NPJ Breast Cancer|June 8, 2026
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancerFrançois-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030Heather A Parsons, Timothy Blewett, Xiangying Chu, et al.
Cancer|January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
JAMA Oncology|August 21, 2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) TrialJennifer A Ligibel, Karla V Ballman, Linda McCall, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Pageof 12

Showing results (101-110 of 120) with videos related to

Sort By:
Pageof 12
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2017
A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67Bojana Jovanović, Ingrid A Mayer, Erica L Mayer, et al.
JAMA Oncology|March 9, 2023
Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical TrialTufia C Haddad, Vera J Suman, Antonino B D'Assoro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2021
Reply to T. Shimoi et al and Y. Shimanuki et alIngrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
Journal of the National Cancer Institute|December 7, 2023
Taxanes for the treatment of breast cancer during pregnancy: an international cohort studyAna S Ferrigno Guajardo, Bryan F Vaca-Cartagena, Erica L Mayer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 7, 2021
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131Ingrid A Mayer, Fengmin Zhao, Carlos L Arteaga, et al.
NPJ Breast Cancer|June 8, 2026
SERENA-6 interpretation and clinical implications: intercepting endocrine resistance in metastatic breast cancerFrançois-Clement Bidard, Carlos Barrios, Giampaolo Bianchini, et al.
Medrxiv : the Preprint Server for Health Sciences|March 22, 2023
Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030Heather A Parsons, Timothy Blewett, Xiangying Chu, et al.
Cancer|January 18, 2024
Adjuvant platinum versus capecitabine for residual, invasive, triple-negative breast cancer: Patient-reported outcomes in ECOG-ACRIN EA1131Karen L Smith, Fengmin Zhao, Ingrid A Mayer, et al.
JAMA Oncology|August 21, 2025
Impact of a Weight Loss Intervention on 1-Year Weight Change in Women With Stage II/III Breast Cancer: Secondary Analysis of the Breast Cancer Weight Loss (BWEL) TrialJennifer A Ligibel, Karla V Ballman, Linda McCall, et al.
The Lancet. Oncology|March 19, 2019
Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trialPanagiotis A Konstantinopoulos, William T Barry, Michael Birrer, et al.
Pageof 12